CA-CREATIVE-ARTISTS
17.4.2017 20:06:17 CEST | Business Wire | Press release
Creative Artists Agency (CAA), the world’s leading entertainment and sports agency, has partnered with CMC Capital Partners (CMC), China’s leading investment fund in media and entertainment, Internet and mobile, and lifestyle. The robust partnership includes the formation of CAA China, a world-class media and entertainment platform, and a minority strategic investment by CMC in CAA. Creating alignment throughout the agency, CMC Chairman Li Ruigang will join CAA’s Board of Directors.
Majority-owned by CAA, CAA China combines the expertise and vast resources of CAA with the broad reach and network of CMC in Greater China. CMC’s tremendous market experience in entertainment and sports combined with CAA’s representation of top Chinese talent, in addition to its leadership in film finance, will create a wide spectrum of new business and client opportunities in the swiftly growing Chinese market, ranging from talent representation, endorsements, and sports, to digital media, music, and original content production.
With more than two dozen employees in Beijing, CAA opened its China office in 2005 and has successfully built out its multiplatform approach to the market. The company has been at the center of every major Chinese co-production for the past 10 years and has packaged, sold, or raised financing for more than 75 Chinese-language film projects. CAA's Global Film Finance & Sales Group has directed more than $400 million in Chinese capital into English-language content. In addition, under the leadership of Jonah Greenberg, who runs the agency’s China efforts in motion pictures, CAA represents many of the most accomplished actors, directors, writers, and producers from Mainland China, Taiwan and Hong Kong, including Zhang Yimou, Lin Chi-ling, and Donnie Yen, among others.
“For more than a decade, we have served as a vital bridge to and within the Chinese market, utilizing our deep experience and network to support the work of the region’s best artists and to develop opportunities within the market for international talent,” said CAA President Richard Lovett. “CAA China will supercharge our efforts, from motion pictures, television, endorsements, and brand consulting to sports, live events, digital media, and beyond. CMC, under the leadership of Li Ruigang, has a remarkable record of success in the region, and we are confident that our partnership will yield tremendous results for our clients and future business partners in China.”
“We believe China and the US are the two biggest entertainment markets and play pivotal roles on the global landscape. The partnership not only creates commercial and industry value, but also serves as an innovative force in the evolution of the Chinese media industry,” said CMC Chairman Li Ruigang. “CAA is a prominent institution in the US entertainment and sports sector, which has built its success on systematically and consistently enabling the success of their clients throughout the years. We are immensely excited about the potential possibilities of an enhanced China angle by CMC coupled with the experience and resources of CAA. CMC has been in a highly productive cooperation with CAA under the leadership of Richard Lovett, and we look forward to greater accomplishments in the future.”
Founded by Li in 2010, CMC is a leading investor in media and entertainment, Internet and mobile, and lifestyle sectors in China. With a deep understanding of the China market, an extensive network of industry resources and prominent operational capabilities, CMC has invested and operated in Greater China, North America, Europe and Asian markets, and has created and supported the growth of many champions and emerging leaders in film, television, animation, kids content, sports, music, fashion, games, location-based entertainment, cinema, digital media, social platform, and entertainment technology. CMC’s previous and current investment and operational portfolio includes IMAX China; Star China, China’s top variety production company; Flagship, a joint venture studio with Warner Bros.; and City Football Group, a football club management company that owns Manchester City Football Club and New York City Football Club. Prior to founding CMC, Li was the Chairman and CEO of Shanghai Media Group (SMG) for more than ten years and successfully transformed SMG from a provincial broadcaster into a leading media conglomerate in China.
“CAA China demonstrates the vision and innovation that has driven CAA’s growth and fueled its ability to stay on the leading edge of industry trends,” said Jim Coulter, co-founder of private equity firm TPG, CAA’s majority shareholder. “CAA has had a significant impact on the Chinese entertainment marketplace by enabling its clients’ success over the past 12 years. We are thrilled with the company’s progress and the value-creation CAA has realized for its shareholders since our investment. With CMC as a meaningfully invested partner, and continuing growth in the Chinese market, the potential for CAA China is limitless.”
Greenberg will continue to lead CAA’s China efforts in motion pictures, working with the existing team in the Beijing office. Roeg Sutherland, Co-Head of CAA’s Global Film Finance and Sales Group, will continue to lead the agency’s film finance business in the market. CAA China will progressively add additional senior management to help expand the business into new entertainment and sports areas.
About Creative Artists Agency
Leading entertainment and sports agency Creative Artists Agency (CAA) represents many of the most successful professionals working in film, television, music, theatre, video games, sports, and digital content, and provides a range of strategic marketing and consulting services to corporate clients. CAA is also a leader in sports, representing more than 1,000 of the world’s top athletes in football, baseball, basketball, hockey, soccer, tennis, Olympics and action sports, and golf, and works in the areas of broadcast rights, corporate marketing initiatives, licensing, and sports properties for sales and sponsorship opportunities.
About CMC
CMC, founded and chaired by Li Ruigang, is China's leading investment and operating platform in media & entertainment, Internet & mobile, and lifestyle, and invests and operates in Greater China, north America, Europe and Asian markets. With a deep understanding of the China market, an extensive network of industry resources and prominent operational capabilities, CMC has created and supported the growth of many industry leaders in subsectors including film, television, animation, sports, music, fashion, games, advertising, marketing, financial media, location-based entertainment, cinema, online video platforms, OTT, smart TV and social media.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170417005739/en/
Contact:
Creative Artists Agency
424.288.2000
Michael Mand, Mmand@caa.com
Beth
McClinton, Beth.McClinton@caa.com
Missy
Davy, Mdavy@caa.com
or
CMC
Jiaming
Wu, Jiaming.Wu@cmccap.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
